SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance

U.S. Markets close in 2 hrs 41 mins

Sanofi (SNY)


NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
45.37-0.01 (-0.02%)
As of 1:19PM EDT. Market open.
People also watch
NVSGSKAZNLLYNVO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close45.38
Open45.24
Bid0.00 x
Ask0.00 x
Day's Range45.18 - 45.95
52 Week Range36.81 - 45.95
Volume1,837,701
Avg. Volume1,734,090
Market Cap112.13B
Beta0.76
PE Ratio (TTM)23.45
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.58 (3.53%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters9 minutes ago

    FDA approves Regeneron, Sanofi $37,000 per year eczema drug

    The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies. Sanofi and Regeneron said the drug, Dupixent, will have a list price of $37,000 a year. "We are encouraged by the ongoing conversations we've had with health plans and pharmacy benefit managers about coverage for Dupixent for patients," Sanofi said in a statement.

  • The Wall Street Journal1 hour ago

    [$$] FDA Approves Regeneron and Sanofi's Dupixent for Eczema

    Regeneron Pharmaceuticals and Sanofi said they will charge $37,000 annually in the U.S. for their newly approved eczema drug, a price the companies said they reached after months of negotiations with pharmacy ...

  • American City Business Journals1 hour ago

    FDA approves Sanofi Genzyme drug amid questions over patent, cost

    The FDA has approved a drug to treat eczema made by Cambridge-based Sanofi Genzyme that some analysts believe could eventually surpass $3 billion in annual sales. The agency announced Tuesday that it has approved dupilumab, a treatment for atopic dermatitis that will be sold under the brand name Dupixent. The drug was developed by Sanofi Genzyme, a division of French pharmaceutical giant Sanofi SA (SNY), along with its partner Regeneron Pharmaceuticals (REGN).